These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25002634)

  • 1. Enzalutamide before chemotherapy prolongs survival.
    Cancer Discov; 2014 Jul; 4(7):OF5. PubMed ID: 25002634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
    Pal SK; Sartor O
    Nat Rev Clin Oncol; 2014 Sep; 11(9):504-6. PubMed ID: 25073005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
    Graff JN; Gordon MJ; Beer TM
    Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract]   [Full Text] [Related]  

  • 5. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
    Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
    Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
    Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
    Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
    Kimura G; Yonese J; Fukagai T; Kamba T; Nishimura K; Nozawa M; Mansbach H; Theeuwes A; Beer TM; Tombal B; Ueda T
    Int J Urol; 2016 May; 23(5):395-403. PubMed ID: 27018069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
    Beer TM; Armstrong AJ; Rathkopf D; Loriot Y; Sternberg CN; Higano CS; Iversen P; Evans CP; Kim CS; Kimura G; Miller K; Saad F; Bjartell AS; Borre M; Mulders P; Tammela TL; Parli T; Sari S; van Os S; Theeuwes A; Tombal B
    Eur Urol; 2017 Feb; 71(2):151-154. PubMed ID: 27477525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
    Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
    Pilon D; Queener M; Lefebvre P; Ellis LA
    J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
    Papazoglou D; Wannesson L; Berthold D; Cathomas R; Gillessen S; Rothermundt C; Hasler L; Winterhalder R; Barth A; Mingrone W; Nussbaum CU; von Rohr L; von Burg P; Schmid M; Richner J; Baumann S; Kühne R; Stenner F; Rothschild SI
    Clin Genitourin Cancer; 2017 Jun; 15(3):e315-e323. PubMed ID: 27450512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The modern treatment of metastatic castration-resistant prostate cancer].
    Küronya Z; Biró K; Maráz A; Géczi L
    Magy Onkol; 2019 Mar; 63(1):41-50. PubMed ID: 30889620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.
    Zhang W; Wu TY; Chen Q; Shi XL; Xiao GA; Zhao L; Xu CL; Zhou T; Sun YH
    Asian J Androl; 2017; 19(2):196-202. PubMed ID: 27212123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
    Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B
    Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
    Beer TM; Miller K; Tombal B; Cella D; Phung D; Holmstrom S; Ivanescu C; Skaltsa K; Naidoo S
    Eur J Cancer; 2017 Dec; 87():21-29. PubMed ID: 29096157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of enzalutamide for metastatic castration-resistant prostate cancer.
    Bhattacharya S; Hirmand M; Phung D; van Os S
    Ann N Y Acad Sci; 2015 Nov; 1358():13-27. PubMed ID: 26384731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.
    Jung SI; Kim MS; Jeong CW; Kwak C; Hong SK; Kang SH; Joung JY; Lee SH; Yun SJ; Kim TH; Park SW; Jeon SS; Kang M; Lee JY; Chung BH; Hong JH; Ahn H; Kim CS; Kwon DD
    Investig Clin Urol; 2020 Jan; 61(1):19-27. PubMed ID: 31942459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.